Depressive disorder is one of the common mental disorders, and its occurrence is usually attributed to the combined effects of multiple factors.The single genetic factor can't fully explain the cause of depressive disorder.Family factors have an important impact on the occurrence of depressive disorder, however, the impact of family factors on depressive disorder and its treatment has not been paid enough attention to.This paper reviewed the recent researches on family factors affecting depressive disorder and family therapy for depressive disorder.The results showed that family factors had an impact on depression patients of any age, and adverse family factors were risk factors for the occurrence, sustainable development and recurrence of depressive disorder.Most of the previous studies were horizontal, but few were longitudinal research.Family therapy plays a positive role in the treatment of depressive disorder and has a significant effect on the acute phase of depression except for major depressive disorder (MDD). Family therapy can quickly relieve the symptoms of depression.Further studies on family-based treatment intervention strategies for MDD are needed in the future, and more longitudinal studies are needed to further analysis of the influence of family factors on depressive disorder.

The E (envelope) protein is the smallest structural protein in all coronaviruses and is the only viral structural protein in which no variation has been detected. We conducted genome sequencing and phylogenetic analyses of SARS-CoV. Based on genome sequencing, we predicted the E protein is a transmembrane (TM) protein characterized by a TM region with strong hydrophobicity and alpha-helix conformation. We identified a segment (NH2-_L-Cys-A-Y-Cys-Cys-N_-COOH) in the carboxyl-terminal region of the E protein that appears to form three disulfide bonds with another segment of corresponding cysteines in the carboxyl-terminus of the S (spike) protein. These bonds point to a possible structural association between the E and S proteins. Our phylogenetic analyses of the E protein sequences in all published coronaviruses place SARS-CoV in an independent group in Coronaviridae and suggest a non-human animal origin.
Amino Acid Sequence ; Base Sequence ; Cluster Analysis ; Codon ; genetics ; Gene Components ; Genome, Viral ; Membrane Glycoproteins ; metabolism ; Membrane Proteins ; genetics ; metabolism ; Molecular Sequence Data ; Phylogeny ; Protein Conformation ; SARS Virus ; genetics ; Sequence Alignment ; Sequence Analysis, DNA ; Sequence Homology ; Spike Glycoprotein, Coronavirus ; Viral Envelope Proteins ; genetics ; metabolism

OBJECTIVE： To evaluate the efficacy and safety of icotinib in the treatment of advanced non-small cell lung cancer （NSCLC）， and to provide evidence-based reference for clinical drug use. METHODS： Retrieved from the Cochrane library， PubMed， Sciencedirect， CNKI， Wanfang database and VIP， RCTs about icotinib or icotinib combined with routine treatment or with other drugs （trial group） versus routine treatment or other drugs （control group） in the treatment of advanced NSCLC were collected. After literature screening， data extraction and literature quality evaluation with Cochrane collaboration bias risk assessment tool 5.1.0， Meta-analysis was performed by using Rev man 5.3 statistical software. RESULTS： A total of 27 RCTs were included， involving 2 345 patients. Results of Meta-analysis showed that response rate [OR＝1.64， 95％CI（1.36， 1.97）， P＜0.000 01] and disease control rate [OR＝1.68， 95％CI（1.39， 2.04）， P＜0.000 01] in trial group were significantly higher than control group； the incidence of ADR in trial group [OR＝0.59， 95％CI（0.48， 0.72）， P＜0.000 01] was significantly lower than control group. CONCLUSIONS： Icotinib shows good efficacy and safety in the treatment of advanced NSCLC.